Photon-counting CT for Intracranial Stent Assessment

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age5-90
SponsorXin Lou

About this trial

Intracranial atherosclerotic disease is an important cause of ischemic stroke, and intracranial stent implantation is increasingly used for patients with severe stenotic lesions. Evaluation of stent patency and detection of in-stent restenosis are essential during follow-up. Digital subtraction angiography (DSA) remains the reference standard for intracranial stent assessment; however, it is an invasive procedure associated with potential complications and radiation exposure. Conventional CT angiography may be limited by stent-related artifacts, including blooming artifact and beam-hardening effects, which can impair accurate evaluation of the stent lumen.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥18 years;

Patients with previously implanted intracranial arterial stents;

Undergoing follow-up CTA examination;

Available imaging data for analysis.

Disqualifiers

Severe motion artifacts;

Poor contrast enhancement;

Incomplete clinical or imaging data.

Trial population

Patients with intracranial arterial stents

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

200 Participants
are grouped into 1 trial group
Group A: Patients with intracranial arterial stents

Trial outcomes

Primary outcomes

1

Sensitivity of UHR PCD-CTA for detecting significant in-stent stenosis

Sensitivity of ultra-high-resolution photon-counting detector CT angiography (UHR PCD-CTA) for detecting significant in-stent stenosis (≥50%), using digital subtraction angiography (DSA) as the reference standard.

Time frame
1-4years

Secondary outcomes

1

Diagnostic accuracy of UHR PCD-CTA for detecting significant in-stent stenosis

Diagnostic accuracy of UHR PCD-CTA for detecting significant in-stent stenosis (≥50%), using DSA as the reference standard.

Time frame
1-4years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Xin Lou

Lead sponsor

Chinese PLA General Hospital

Sponsor institution